Posted by Michael Wonder on 15 Dec 2020
Imfinzi recommended for approval in the EU by CHMP for less-frequent, fixed-dose use in unresectable non-small cell lung cancer
15 December 2020 - Option would extend dosing from two to four weeks, reducing medical visits and improving patient convenience
AstraZeneca's Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union for an additional dosing option, 1,500 mg fixed dose every four weeks, in the approved indication of locally advanced, unresectable non-small cell lung cancer in adults whose tumours express PD-L1 on at least 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy.
